Colorado BioScience Association Appoints New Board of Directors Leaders from OrganiShield and General Inception
By: Colorado BioScience Association Date: 03/15/2024
For Immediate Release: March 19, 2024 Executives from Colorado State University, KBI Biopharma, Metro Denver Economic Development Corporation, Terumo Blood and Cell Technologies, and STAQ Pharma Join...
Learn MoreWeekly Policy Blog: Campaign & Legislation Support Colorado’s Drive to Be a Leading Life Sciences Hub
By: Colorado BioScience Association Date: 03/11/2024
Colorado BioScience Association and a consortium of 22 Colorado partners have launched Colorado Hub for Health Impact, a new national economic development campaign to position Colorado as America’s ep...
Learn MoreWeekly Policy Blog: CBSA’s 2024 Day at the Capitol
By: Colorado BioScience Association Date: 03/04/2024
CBSA held its annual Day at the Capitol event on February 28. CBSA members, legislators, and legislative staff first gathered for a health innovation company showcase and networking, which highlighted...
Learn MoreFitzsimons Innovation Community Partners with the Colorado Hub for Health Impact Campaign
By: Colorado BioScience Association Date: 03/04/2024
Colorado’s health and life sciences industry gets a nationwide spotlight. If it has to do with health and innovation in Colorado, Fitzsimons Innovation Community is bound to be a part of it. We are es...
Learn MoreNew Consortium Launches Colorado Hub for Health Impact, a National Economic Development Campaign to Attract Health Innovation Companies to the State
By: Colorado BioScience Association Date: 02/27/2024
For Immediate Release: February 27, 2024 NEWS RELEASE 20+ Life Sciences Organizations, Economic Development Groups, Local Governments, Developers, and Builders Invest to Bring New, High-Growth Compani...
Learn MoreWeekly Policy Blog: PDAB Initiates Upper Payment Limit Rulemaking Process for the First Time
By: Colorado BioScience Association Date: 02/26/2024
On Friday, February 23, the Colorado Prescription Drug Affordability Board (PDAB or Board) decided to initiate an “upper payment limit” (UPL) rulemaking process for the autoimmune disease drug Enbrel...
Learn MoreWeekly Policy Blog: PDAB Deems One of Two Drugs “Unaffordable” in Recent Affordability Decisions
By: Colorado BioScience Association Date: 02/19/2024
On Friday, February 16, the Colorado Prescription Drug Affordability Board (PDAB or Board) completed its second and third affordability reviews, following its first decision on December 8 that the cys...
Learn MoreWeekly Policy Blog: Legislative Session Update
By: Colorado BioScience Association Date: 02/05/2024
The first few weeks of the Colorado legislative session require intensive engagement at the Capitol and comprehensive review of proposed legislation by CBSA's Policy + Advocacy team to support a colla...
Learn MoreFitzsimons Innovation Community Presents Our Third Annual Innovation Report
By: Colorado BioScience Association Date: 02/05/2024
A look at the accomplishments, progress, and innovation behind the buzz. At Fitzsimons Innovation Community, we know January is one of the best times to look forward, set goals, and make plans for the...
Learn MoreWeekly Policy Blog: Take Action to Protect America’s Innovation Economy
By: Colorado BioScience Association Date: 01/29/2024
CBSA urges you to take action now to protect America’s innovation economy! The federal government is considering the use of “march-in rights” (where it could compel a patent-owner to license an invent...
Learn More